Safety Profile of RINVOQ™ (upadacitinib): Analysis of Up to ~3.5 Years of Exposure in Patients With Rheumatoid Arthritis
Sponsored by AbbVie Medical Affairs
Jul 01, 2020
Gout/Crystal
Autoinflammatory/Still's Disease Panel - EULAR2020
Drs. Olga Petryna, Petros Efthimiou, Apostolos Kontzias and Jack Cush discuss autoinflammatory highlights from the Virtual EULAR 2020 meeting June 3-6
Gout Review from EULAR2020
Dr. Olga Petryna reviews highlights from the virtual EULAR 2020 meeting June 3-6, 2020
Dr. John Cush RheumNow
1 month ago
When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020
k dao KDAO2011
1 month ago
#EULAR2020 ABST#OP0015Plenary session: very low serum urate < 4 mg/dL in men assc w/increased CV mortality; 40,000 pt study. NOTE: this may be driven by poorly controlled diabetes as hyperglycemia has a uricosuric effect; from NHANES database @MassGeneralNews @RheumNow https://t.co/jnhkS436JZ
Dr. John Cush RheumNow
1 month ago
When starting IV Pegloticase in #Gout, Do you start a DMARD too? #EULAR2020
Therapeutic Update
Presented here is an update on the longer-term safety profile of upadacitinib, drawing on the integrated analysis of up to ~3.5 years of exposure data from five Phase 3 studies. Dr. Winthrop and Dr. Cush provide additional information from relevant EULAR 2020 posters.
Read Post
